^
Association details:
| Biomarker: | EGFR wild-type |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | docetaxel (Tubulin polymerization promoter, Microtubule stabilizer) + plinabulin (BPI 2358) (GEF-H1 activator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Subgroup analysis in patients (pts) with non-squamous (N-Sq), EGFR-wild type (wt), second/third-line NSCLC from the global phase (Ph) 3 trial DUBLIN-3 (BPI-2358-103) with the plinabulin/docetaxel (Plin/Doc) combination versus Doc alone.
Published date:
05/26/2022
Excerpt:
The median OS benefit is 2.6 months (p = 0.023)….The addition of Plin to Doc was superior to SoC Doc alone for efficacy and safety in the clinically relevant subgroup of non-squamous EGFR-wild type, 2nd/3rd line NSCLC pts.
DOI:
10.1200/JCO.2022.40.16_suppl.9090
Trial ID:
